Kane Biotech Inc.
KNE.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -15.20K | 6.20K | 20.20K | 287.40K | 89.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.20K | 6.20K | 20.20K | 287.40K | 89.90K |
| Cost of Revenue | -20.60K | 9.90K | 53.10K | 257.90K | 152.20K |
| Gross Profit | 5.40K | -3.70K | -32.90K | 29.60K | -62.30K |
| SG&A Expenses | 374.50K | 274.90K | 101.00K | 656.70K | 232.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 436.40K | 400.70K | 219.30K | 1.10M | 672.40K |
| Operating Income | -451.50K | -394.60K | -199.10K | -809.00K | -582.50K |
| Income Before Tax | -469.70K | -441.00K | -251.90K | -849.00K | -773.60K |
| Income Tax Expenses | -77.50K | -- | -- | -- | -936.00K |
| Earnings from Continuing Operations | -392.30K | -441.00K | -251.90K | -849.00K | 162.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -936.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -392.30K | -441.00K | -251.90K | -849.00K | -773.60K |
| EBIT | -451.50K | -394.60K | -199.10K | -809.00K | -582.50K |
| EBITDA | -440.50K | -323.80K | -165.60K | -797.00K | -559.00K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 181.60M | 339.16M | 163.03M | 150.06M | 104.77M |
| Average Diluted Shares Outstanding | 181.60M | 339.16M | 180.51M | 150.06M | 104.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |